Renal and systemic effects of chronic blockade of ETA or ET B in normal rats and animals with experimental heart failure

Bahaa Francis, Joseph Winaver, Tony Karram, Aaron Hoffman, Zaid Abassi

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Endothelin-1 (ET-1) is involved in the pathogenesis of cardiac and renal hemodynamic changes and impaired excretory function in congestive heart failure. It has previously been demonstrated that acute administration of ABT-627 (endothelin-A blocker) abolished systemic and renal vasoconstriction in controls and rats with congestive heart failure induced by a surgically created aortocaval fistula (Abassi et al. Clin Sci (Lond) 2002;103:S245-S248). In contrast, acute endothelin-B blockade by A-192621 exaggerated the ET-1 induced systemic and renal vasoconstriction. The present study examined the renal and systemic effects of chronically administered ABT-627 (24 mg/kg per day) or A-192621 (72 mg/kg per day) for 7 days via osmotic minipumps inserted intraperitoneally on the day of operation of sham controls and rats with congestive heart failure. Tailcuff measurements revealed that ABT-627 significantly decreased mean arterial pressure from 108 ± 2 mmHg to 87 ± 2 mmHg (P < 0.05), whereas A-192621 significantly increased mean arterial pressure from 110 ± 3 mmHg to 122 ± 3 mmHg (P < 0.05) in controls. Despite the hypotensive effect of ABT-627, daily sodium excretion dramatically increased, but to a lesser extent in A-192621-treated controls. Furthermore, chronic administration of ABT-627 to controls attenuated the systemic and renal vasoconstriction induced by ET-1 (1 nmol/kg intravenous), whereas A-192621 augmented these effects. Similarly, chronic treatment with ABT-627 totally abolished the systemic and renal vasoconstriction caused by injected ET-1 in rats with congestive heart failure, whereas A192621 potentiated these effects. Chronic treatment of animals with congestive heart failure with ABT-627 did not influence daily sodium excretion, whereas treatment with A192621 significantly improved daily sodium excretion. Interestingly, treatment with either ABT-627 or A192621 significantly decreased cardiac hypertrophy in rats with congestive heart failure. In conclusion, in sham controls endothelin-B receptor mediated vasodilation and natriuresis, probably as a result of tubular action, whereas in congestive heart failure the excretory contribution of endothelin-B receptor was attenuated, resulting in Na+ retention.

Original languageEnglish
Pages (from-to)S54-S58
JournalJournal of Cardiovascular Pharmacology
Volume44
Issue numberSUPPL. 1
DOIs
StatePublished - Nov 2004
Externally publishedYes

Keywords

  • Endothelin
  • Endothelin receptors
  • Heart failure
  • Kidney
  • Rat

Fingerprint

Dive into the research topics of 'Renal and systemic effects of chronic blockade of ETA or ET B in normal rats and animals with experimental heart failure'. Together they form a unique fingerprint.

Cite this